Brooks-LaSure Continues Press To Extend Insulin Caps To Commercial Market

CMS Administrator Chiquita Brooks-LaSure told Inside Drug Pricing the agency will continue to work with lawmakers to make insulin affordable for all Americans after a newly issued HHS report found the Inflation Reduction Act’s $35 monthly out-of-pocket insulin cost cap for those with Medicare could have saved beneficiaries an average of $500 across Parts B and D had it been applied in 2020. Brooks-LaSure said the HHS report shows the impact insulin copay caps could also have in private...